menu
    • menu
    [{"orgOrder":0,"company":"Villaris Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Auremolimab","moa":"CD122","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Villaris Therapeutics","amount2":1.4299999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":1.4299999999999999,"dosageForm":"","sponsorNew":"Villaris Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Villaris Therapeutics \/ Incyte Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Villaris Therapeutics

    Menu

    Villaris Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Villaris Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Villaris Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Auremolimab

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Incyte Corporation

                            Deal Size : $1,430.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Incyte Announces Agreement to Acquire Medicxi-Backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-1...

                            Details : Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize auremolimab (VM6, an anti-IL-15Rβ monoclonal antibody) for all uses, including in vitiligo and other autoimmune and inflammatory ...

                            Brand Name : VM6

                            Molecule Type : Large molecule

                            Upfront Cash : $70.0 million

                            October 03, 2022

                            Lead Product(s) : Auremolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Incyte Corporation

                            Deal Size : $1,430.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth